Study study type
PathologyT1T0Patientssample sizesROB Results

es-BC - HER2 positive - (neo)adjuvant (NA) breast cancer - HER2-positive es-BC - HER2 positive - (neo)adjuvant (NA)

versus paclitaxel followed by doxorubicin plus cyclophosphamide, pertuzumab plus trastuzumab, placebo
pertuzumab plus trastuzumab
IMpassion-050, 2022
  NCT03726879		RCTes-BC - HER2 positive - (neo)adjuvant (NA)Atezolizumab plus SOCPlacebo plus SOCPatients ≥ 18 years old with a primary tumor of > 2 cm, positive lymph node status and histologically confirmed Early Her2-Positive Breast Cancer226 / 228low
 inconclusive
  • inconclusive 1 % decrease in pCR (PE)
  • inconclusive 33 % decrease in pCR (PE)
Atezolizumab with neoadjuvant dose-dense doxorubicin/cyclophosphamide–paclitaxel and PH for high-risk, HER2-positive early breast cancer did not increase pCR rates versus placebo in the ITT or PD-L1–positive populations

la/mBC - HER2 positive - 1st Line (L1) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 1st Line (L1)

versus trastuzumab
pertuzumab plus trastuzumab
PERTAIN, 2018
  NCT01491737		RCTla/mBC - HER2 positive - 1st Line (L1)pertuzumab plus trastuzumab plus an AI (letrozole or anastrozole)trastuzumab plus an AI (letrozole or anastrozole)Postmenopausal patients, with first-line HER2-positive and HR positive disease129 / 129NA
 conclusif
  • demonstrated 35 % decrease in progression or deaths (PFS) (PE)

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons